Apexigen was a clinical-stage biopharmaceutical company that focused on the discovery and development of innovative antibody therapeutics for oncology. Their proprietary APXiMAB™ antibody discovery platform was designed to generate a diverse range of humanized monoclonal antibodies with the potential to activate the immune system or directly target tumor cells. Key pipeline candidates included sotigalimab (a CD40 agonist) and APX601 (a TNFR2 antagonist). In August 2023, Apexigen was acquired by Pyxis Oncology, Inc. This profile reflects Apexigen's operations and status prior to and leading up to its acquisition.
The headquarters served as the central hub for Apexigen's research and development, clinical trial management, and corporate operations, focusing on advancing its pipeline of antibody-based cancer therapies.
Located in a biotech-focused business park, the facility likely featured specialized laboratory spaces for antibody discovery and preclinical development, alongside office facilities for clinical, regulatory, and administrative teams.
As a clinical-stage biopharmaceutical company, the work culture at Apexigen likely emphasized scientific rigor, innovation, collaboration, and a strong sense of mission towards developing new cancer treatments. It would have been a dynamic and fast-paced environment driven by research milestones and clinical development timelines.
The San Carlos headquarters was significant as the epicenter of Apexigen's efforts to leverage its APXiMAB™ platform and develop novel immunotherapies, contributing to the broader biotech ecosystem in the Bay Area before its acquisition.
Prior to its acquisition by Pyxis Oncology, Apexigen's global presence was primarily characterized by its clinical trial activities. While its physical R&D and corporate operations were centered in the United States, its clinical studies for drug candidates like sotigalimab often involved trial sites, investigators, and collaborations in multiple countries. This was necessary to ensure diverse patient populations and meet global regulatory standards for drug development, rather than maintaining a network of international offices.
75 Shoreway Road, Suite C
San Carlos
CA
USA
Address: N/A
The company's focus was on leveraging the biotech ecosystem of the San Francisco Bay Area from its primary location.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Apexigen' leadership includes:
Apexigen has been backed by several prominent investors over the years, including:
The most significant executive event for Apexigen was its acquisition by Pyxis Oncology, completed in August 2023. This event led to the transition and departure of the Apexigen executive team as the company was integrated into Pyxis Oncology. There were no new executive hires into Apexigen's standalone leadership in its final months.
Discover the tools Apexigen uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Pyxis Oncology, Apexigen, Inc. likely utilized common corporate email formats. Based on patterns observed for similar biotech companies, a frequently used format was the first initial followed by the last name. The success rate is an estimated historical figure and is not applicable currently.
(first_initial)(last)@apexigen.com
Format
jdoe@apexigen.com
Example
75%
Success rate
GlobeNewswire (Pyxis Oncology) • August 8, 2023
Pyxis Oncology announced the successful completion of its acquisition of Apexigen, Inc. This strategic move aimed to enhance Pyxis's pipeline with Apexigen's antibody therapeutics, notably sotigalimab, a CD40 agonist....more
GlobeNewswire (Apexigen, Inc.) • August 4, 2023
Apexigen, Inc. announced that its stockholders voted to approve the previously announced merger agreement with Pyxis Oncology, a critical step towards the finalization of the acquisition....more
GlobeNewswire (Pyxis Oncology/Apexigen) • May 10, 2023
Pyxis Oncology and Apexigen jointly announced they had entered into a definitive agreement for Pyxis to acquire Apexigen. The transaction was intended to combine their expertise and pipelines in oncology....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Apexigen, are just a search away.